Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by DMC Group LLC

DMC Group LLC decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4.0% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,261 shares of the biotechnology company’s stock after selling 136 shares during the quarter. DMC Group LLC’s holdings in Sarepta Therapeutics were worth $407,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Mather Group LLC. bought a new position in Sarepta Therapeutics during the first quarter valued at about $28,000. Riggs Asset Managment Co. Inc. grew its stake in shares of Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares during the last quarter. Innealta Capital LLC bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $31,000. New Covenant Trust Company N.A. acquired a new stake in Sarepta Therapeutics during the first quarter valued at approximately $32,000. Finally, GAMMA Investing LLC lifted its stake in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 87 shares during the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on SRPT shares. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Raymond James reissued an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. UBS Group upped their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $152.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 20th. Finally, Royal Bank of Canada boosted their price target on shares of Sarepta Therapeutics from $181.00 to $182.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Two analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $183.89.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Trading Up 2.3 %

Shares of NASDAQ SRPT opened at $127.08 on Friday. The business has a 50 day simple moving average of $129.00 and a 200 day simple moving average of $132.36. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $173.25. The stock has a market cap of $12.01 billion, a price-to-earnings ratio of 1,155.27 and a beta of 0.82. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.27) earnings per share. On average, research analysts predict that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.